Bioanalytical Systems, Inc. d/b/a Inotiv Appoints Beth A. Taylor as New Chief Financial Officer
March 09 2020 - 4:45PM
Bioanalytical Systems, Inc. (NASDAQ: BASI), operating as Inotiv
(the “Company” or “Inotiv”), today announced the appointment of
Beth A. Taylor, CPA, as Vice President - Finance and Chief
Financial Officer of the Company. Ms. Taylor succeeds Jill C.
Blumhoff, who had served as the Company’s Vice President - Finance
and Chief Financial Officer since May 2016.
Ms. Taylor joins the Company with an extensive background in
corporate and operational finance and accounting, including as Vice
President of Finance and Chief Accounting Officer for Endocyte,
Inc. Ms. Taylor possesses exceptional experience and expertise in
business planning, technical accounting, compliance, and investor
relations for public companies, and a successful track record of
cultivating support and relationships within organizations to
achieve goals.
“I am pleased to welcome Beth to our team and look forward to
her contributions in driving our shared vision for growth and
success,” said Company President and Chief Executive Officer Robert
Leasure, Jr. “Beth has the experience and business acumen necessary
to lead the Company’s financial and accounting team with the goal
of continuing to increase confidence and shareholder value for our
evolving Company. I would also like to thank Jill Blumhoff for her
hard work and dedication to the Company and wish her well in her
future endeavors,” concluded Mr. Leasure.
“It is a very exciting time to be joining Inotiv, with the
recent growth and investment in internal operations and through
strategic acquisitions to better serve and grow our client base
through an increased scope of services,” said Ms. Taylor. “I am
eager to join the Inotiv team and assist with strategic
growth iniatives. I look forward to contributing to the team’s
effort towards making investments to deliver excellent experiences
to our clients, and ultimately to drive long-term shareholder
value.”
Prior to joining Inotiv, Ms. Taylor held progressively
responsible VP of Finance, Controllership and other financial
leadership positions at Endocyte, Inc., Author Solutions, Inc.,
Harlan Laboratories, Inc., Republic Airways Holdings and
Rolls-Royce Corporation. Ms. Taylor started her career in audit
with Deloitte and received her B.S. in Accounting from Indiana
University’s Kelly School of Business in Bloomington, Indiana.
About the Company
Bioanalytical Systems, Inc., operating as Inotiv,
is a pharmaceutical development company providing contract research
services and monitoring instruments to emerging pharmaceutical
companies and the world's leading drug development companies and
medical research organizations. The Company focuses on developing
innovative services supporting its clients’ discovery and
development objectives for improved decision-making and accelerated
goal attainment. The Company’s products focus on increasing
efficiency, improving data, and reducing the cost of taking new
drugs to market. Visit inotivco.com for more information about
the Company.
This release may contain forward-looking statements
that are subject to risks and uncertainties including, but not
limited to, risks and uncertainties related to changes in the
market and demand for our products and services, the development,
marketing and sales of products and services, changes in
technology, industry and regulatory standards, the timing of
acquisitions and the successful closing, integration and business
and financial impact thereof, and various market and operating
risks, including those detailed in the Company's filings with the
U.S. Securities and Exchange Commission.
Company Contact:William
PitchfordChief Human Resources OfficerPhone:
765.250.9603bpitchford@inotivco.com
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2023 to Apr 2024